Canada - English - Health Canada

jubilant generics limited - olanzapine - tablet - 15mg - olanzapine 15mg - atypical antipsychotics

Canada - English - Health Canada

jubilant generics limited - olanzapine - tablet - 20mg - olanzapine 20mg - atypical antipsychotics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - chlordiazepoxide hydrochloride - oral capsule - 10mg

Ireland - English - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium thiosulfate; sodium nitrite - solution for injection - 30/250 milligram(s)/millilitre - antidotes; thiosulfate; sodium nitrite

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xepa-soul pattinson (malaysia) sdn bhd - rosuvastatin calcium -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xepa-soul pattinson (malaysia) sdn bhd - rosuvastatin calcium -

Israel - English - Ministry of Health

neopharm ltd, israel - lonafarnib - hard gelatin capsules - lonafarnib 50 mg - lonafarnib - zokinvy is indicated in patients 12 months of age and older with a body surface area (bsa) of0.39 m2 and above:to reduce the risk of mortality in hutchinson-gilford progeria syndrome (hgps)• for the treatment of processing-deficient progeroid laminopathies with either:o heterozygous lmna mutation with progerin-like protein accumulationo homozygous or compound heterozygous zmpste24 mutationslimitations of usezokinvy is not indicated for other progeroid syndromes or processing-proficient progeroid laminopathies. based upon its mechanism of action, zokinvy would not be expected to be effective in these populations.

Israel - English - Ministry of Health

neopharm ltd, israel - lonafarnib - hard gelatin capsules - lonafarnib 75 mg - lonafarnib - zokinvy is indicated in patients 12 months of age and older with a body surface area (bsa) of0.39 m2 and above:to reduce the risk of mortality in hutchinson-gilford progeria syndrome (hgps)• for the treatment of processing-deficient progeroid laminopathies with either:o heterozygous lmna mutation with progerin-like protein accumulationo homozygous or compound heterozygous zmpste24 mutationslimitations of usezokinvy is not indicated for other progeroid syndromes or processing-proficient progeroid laminopathies. based upon its mechanism of action, zokinvy would not be expected to be effective in these populations.